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ABSTRACT: Although the Cu2+-binding sites of the prion protein have been
well studied when the protein is fully saturated by Cu2+, the Cu2+-loading
mechanism is just beginning to come into view. Because the Cu2+-binding modes
at low and intermediate Cu2+ occupancy necessarily represent the highest-aﬃnity
binding modes, these are very likely populated under physiological conditions,
and it is thus essential to characterize them in order to understand better the
biological function of copper−prion interactions. Besides binding-aﬃnity data,
almost no other thermodynamic parameters (e.g., ΔH and ΔS) have been
measured, thus leaving undetermined the enthalpic and entropic factors that
govern the free energy of Cu2+ binding to the prion protein. In this study,
isothermal titration calorimetry (ITC) was used to quantify the thermodynamic
parameters (K, ΔG, ΔH, and TΔS) of Cu2+ binding to a peptide, PrP(23−28,
57−98), that encompasses the majority of the residues implicated in Cu2+
binding by full-length PrP. Use of the buﬀer N-(2-acetomido)-amino-
ethanesulfonic acid (ACES), which is also a well-characterized Cu2+ chelator, allowed for the isolation of the two highest
aﬃnity binding events. Circular dichroism spectroscopy was used to characterize the diﬀerent binding modes as a function of
added Cu2+. The Kd values determined by ITC, 7 and 380 nM, are well in line with those reported by others. The ﬁrst binding
event beneﬁts signiﬁcantly from a positive entropy, whereas the second binding event is enthalpically driven. The thermodynamic
values associated with Cu2+ binding by the Aβ peptide, which is implicated in Alzheimer’s disease, bear striking parallels to those
found here for the prion protein.
■ INTRODUCTION
The normal cellular form of the prion protein (PrPC) is tethered
to the outer surface of neuronal cells through a glycosylphos-
phatidylinositol (GPI) anchor.1 PrPC undergoes endocytosis
where it cycles between the endosome and cell surface,2 and this
is dramatically stimulated by exposure to divalent copper and, to
a lesser extent, zinc.3 The observation that PrP binds Cu2+ in vivo
and the fact that the N-terminal metal-binding region is highly
conserved in mammals strongly suggests the PrP−Cu2+
interaction plays a physiological role.4,5 The speciﬁc interaction
of PrP with Cu2+ serves as a lens through which the normal
function, and possibly the disease causing refolding of PrPC to the
scrapie form (PrPSc), can be studied.
At physiological pH, PrP binds approximately 5 equiv of Cu2+
ions at the unstructured N-terminal half of the protein, residues
60−111.4,6−9 The octarepeat region, residues 60−91, binds 4
equiv of Cu2+ and consists of four sequential repeats of
PHGHGGWGQ.10−12 Immediately following the octarepeats
is a region spanning residues 92−111 that contains two His
residues (His96 and His111) and is involved in the binding of 1
equiv of Cu2+.13−15 Although the structure of the Cu2+-
coordination sphere for the octarepeat region is well established
in its fully Cu2+-saturated state, the precise Cu2+-coordination
sphere of the C-terminal site (the so-called “ﬁfth” or “non-
octarepeat” site) is not as well resolved.
The Cu2+-loading mechanism of the metal-binding domain of
PrP is complex, involving three diﬀerent binding modes, some of
which are composed of multiple isomers, and depends on the
precise ratio of Cu2+ to PrP.16−18 There is consensus that the
initial binding event involves coordination of Cu2+ by multiple
His imidazoles, most of which are located in the octarepeat
region. However, the question as to which His residues are
involved diﬀers between studies because diﬀerent model
peptides have been used, many of which have less than the six
His residues contained in the region of PrP that spans residues
60−111. The second binding event occurs at the nonoctarepeat
site, and any further addition of Cu2+ begins to populate the
individual octarepeat units (HGGGW−Cu2+) at the expense of
the multiple-His binding mode.18−20
Extracellular Cu2+ concentrations in the central nervous
system (CNS) are estimated to be in the low micromolar
range,21−23 and PrP has Kd values ranging from subnanomolar to
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low micromolar.7−9,17,24 Thus, PrP is tuned for binding in this
environment and is responsive to a wide range of copper
concentrations. Deeper insight into the highest-aﬃnity binding
modes, both structurally and thermodynamically, would be
beneﬁcial because they are very likely populated under
physiological conditions where the Cu2+ concentration is low
and/or there are competitors. Although a number of
spectroscopic and spectrometric studies have provided some
structural information about the high-aﬃnity sites, almost no
thermodynamic information is available. A few studies using
isothermal titration calorimetry (ITC) on the binding of Cu2+ by
PrP have been performed from which stoichiometries and Kd
values have been determined.8,19,25 However, other thermody-
namic parameters, such as ΔG, ΔH, and ΔS, have not been
measured, thus leaving the enthalpic and entropic factors
governing the free energy of binding undetermined.
In this Article, ITC was used to quantify the thermodynamic
parameters for Cu2+ binding to PrP(23−28, 57−98) and circular
dichroism (CD) spectroscopy was used to characterize the
diﬀerent binding modes as a function of added Cu2+. This
particular peptide construct was utilized because it encompasses
the majority of the residues implicated in Cu2+ binding by full-
length PrP, and its Cu2+-loading process as well as its Cu2+-
coordination spheres have already been well characterized by our
lab.18,20 The Kd values determined by ITC are well in line with
those reported by others.17,24 Interestingly, the enthalpy
associated with the second binding event (ΔH2 = −37.2 ± 5%
kcal/mol) is signiﬁcantly higher than that of the ﬁrst binding
event (ΔH1 =−3.59± 13% kcal/mol). However, the entropy for
the ﬁrst binding event is positive (TΔS1 = +2.18 ± 23% kcal/
mol), which helps to oﬀset the enthalpy diﬀerence and leads to a
Kd that is 2 orders of magnitude smaller (i.e., higher aﬃnity). The
thermodynamic values associated with Cu2+ binding by the Aβ
peptide,26 implicated in Alzheimer’s disease, bear striking
parallels to those found here for PrP. Thus, a favorable entropy
associated with initial metal binding may be a general property of
highly ﬂexible systems such as PrP and Aβ where equilibria
between coordination spheres exists and multiple histidine
residues are present.
■ EXPERIMENTAL METHODS
Peptide Synthesis. All peptides were prepared by solid-phase
synthesis on an automated PS3 synthesizer (Protein Technologies, Inc.)
using standard ﬂuorenylmethoxycarbonyl (Fmoc) methods, puriﬁed by
reverse-phase HPLC (C18 column), and characterized by electrospray
ionization mass spectrometry on a Micromass Q-ToF micro (Agilent).
The three peptides used for this study are shown in Table 1. All of the
peptides were acetylated at the N-terminus and amidated at the C-
terminus.
Peptide Sample Preparation and Concentration Determi-
nation. Lyophilized peptides were dissolved in buﬀer containing 10
mMN-(2-acetamido)-2-aminoethanesulfonic acid (ACES) at pH 7.4 or
10 mM N-ethylmorpholine (NEM) at pH 7.4. Peptide concentrations
were determined by acquiring UV−vis spectra of the samples. The
extinction coeﬃcient for tryptophan at 280 nm, which was taken as 5690
M−1 cm−1, was used to calculate the peptide concentration. Copper
(Cu2+) was added as CuCl2.
Circular Dichroism Spectroscopy. CD spectra were collected at
room temperature on a J-815 spectrometer (Jasco) with a bandwidth of
4 nm in a 1 cm cell. To ensure accurate background subtraction for each
sample, a background spectrum of the buﬀer was collected immediately
after every run. The PMT high voltage was below 400 V in the range of
290 nm 680 nm. As recommended by Jasco, 400 V was selected as the
threshold beyond which data may be considered excessively noisy and
thus unreliable.
Isothermal Titration Calorimetry. ITC measurements were
carried out at 25 °C on a MicroCal VP-ITC ultrasensitive titration
calorimeter. The solution in the cell was stirred at 307 rpm to ensure
rapid mixing. In each experiment, 8 μL of titrant was delivered to the
reaction cell over 20 s with a 350 s interval between injections to allow
complete equilibration. Titrations were run in triplicate for each peptide
to ensure reproducibility and to allow for statistical analysis. A
background titration consisting of the identical titrant solution but
containing only the buﬀer solution in the sample cell was run for each
reaction (Figure S1). The last ten data points were averaged and
subtracted from each experimental titration to account for the heat of
dilution. The data were subsequently analyzed with a sequential binding
model included in the Origin 7.0 software package supplied by
MicroCal.
■ RESULTS
ACES was used as a buﬀer and as the chelator for Cu2+. To
determine how eﬀective it was at preventing Cu2+ loading of the
octarepeat units, visible CD spectroscopy was utilized to
characterize the diﬀerent binding modes as a function of added
Cu2+. The absorption bands that are due to d−d transitions can
occur over a range of wavelengths, typically 500−750 nm. In CD
spectroscopy, the transitions for Cu2+ typically arise in pairs: one
being a positive band and the other a negative band. CD
spectroscopy has the advantage of being able to resolve
transitions that overlap in regular absorbance spectra, and
these appear as separate bands. The technique is very sensitive to
the metal−ligand sphere, and this is reﬂected by both the
absorbance extrema and the phase associated with the transition
(i.e., positive or negative).27 Furthermore, these transitions
become observable by CD spectroscopy only when Cu2+ is in a
chiral ligand environment; unbound aqueous Cu2+ is not
detected. The CD spectroscopy signals characteristic of the
two diﬀerent coordination spheres populated when PrP(23−28,
57−98) is fully Cu2+-saturated (i.e., HGGGW−Cu2+ and GTH−
Cu2+) have been described previously.10,11,14,17,20,28 Figure 1a
shows the CD spectrum of PrP(23−28, 57−98) with 5 equiv of
Cu2+ in 10 mM ACES. (See Table 1 for peptide sequences.)
At this point in the process, the system is considered to be
saturated with Cu2+ because further addition of the metal (up to
10 equiv of Cu2+) results in no change in the CD signal (data not
shown). It should be noted that the highest-aﬃnity bindingmode
(i.e., that of multiple His residues coordinating a single Cu2+) is
CD silent. The CD signal observed in Figure 1a closely resembles
that of the GTH−Cu2+ complex (Figure 1b) modeled by
PrP(89−98), with the λmax (∼500 nm) values of the positive
bands being almost identical. Here, we focus mainly on the
Table 1. PrP-Derived Peptide Sequencesa
aAll of the peptides were acetylated at the N-terminus and amidated at the C-terminus.
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positive band at 500 nm because the negative band (λmin), which
appears at wavelengths greater than 580 nm, suﬀers from
excessive noise for PrP(23−28, 57−98) (Figure 1a). Above 625
nm, the photomultiplier tube (PMT) high voltage began to
exceed 400 V, which is considered by the instrument
manufacturer to be the threshold beyond which data may be
considered excessively noisy and thus unreliable. However, the
negative diﬀerential absorbances in Figure 1a,b are not dissimilar
because they both appear in the 580−690 nm range. The
additional absorption band, centered at approximately 330 nm
with a positive band near 350 nm and a negative band near 310
nm, is attributable to the ligand-to-metal charge transfer
(LMCT) band arising from the excitation of electrons from
the imidazole group and/or deprotonated amide(s) to the
copper center. These bands are not as informative or as well-
correlated to particular equatorial ligand arrangements for PrP−
Cu2+ complexes as those arising from d−d transitions.20,29
Herein, we note that the intensities of the LMCT bands are
diﬀerent and may reﬂect slight distortions in the equatorial
coordination sphere as a result of diﬀerent peptide models being
used.
Thus, the data suggests that the PrP(23−28, 57−98) peptide
binds two Cu2+ ions and the octarepeat units (i.e., the four
HGGGW segments) fail to out-compete the ACES buﬀer for
Cu2+. To corroborate this conclusion, the visible CD spectrum of
PrP(73−91) in complex with Cu2+ was collected in the absence
(Figure 2) and presence of ACES. Upon the addition of ACES,
the CD signal disappeared (data not shown).
ITC was used to measure the heat associated with the titration
of Cu2+ into PrP(23−28, 57−98) in 10 mMACES buﬀer, pH 7.4
at 298 K. Three separate ITC experiments were performed under
identical conditions. A representative titration is shown in Figure
3, displaying the diﬀerential power signal measured for each
Figure 1. (a) Visible CD spectrum of 0.1 mM PrP(23−28, 57−98) with
0.5 mM Cu2+ added in 10 mM ACES, pH 7.4. (b) Visible CD spectrum
of 0.2 mM PrP(89−98)/Cu2+ in 10 mM NEM, pH 7.4.
Figure 2. Visible CD spectrum of 0.2 mM PrP(73−91)/Cu2+ in 10 mM
NEM, pH 7.4.
Figure 3. ITC binding isotherm for the titration of Cu2+ into 0.1 mM
PrP(23−28, 57−98) in 10 mM ACES, pH 7.4 at 25 °C. The top panel
shows the diﬀerential power signal measured for each injection, and the
bottom panel shows the integrated peak areas corresponding to the
measured heat released for each injection. A theoretical ﬁt is
superimposed on the data and the resulting thermodynamic parameters
are listed in Table S1 (Run 1).
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injection and isotherm (top and bottom, respectively). The
binding isotherm shows saturation behavior with no clear
inﬂection point. This suggests that the Cu2+/PrP ratio is greater
than 1:1 (i.e., there is more than one Cu2+ bound per peptide).
Buﬀer- and pH-dependent binding constants and thermody-
namic values were obtained by ﬁtting of the binding isotherm
(Table 2).
A sequential binding model with two sites (i.e., Cu2+/PrP =
2:1) provides the best ﬁt and is congruent with the stoichiometry
suggested by the CD spectroscopy data, represented as
+ ⇌ −+ + KPrP Cu PrP Cu ;2 2 1 (1)
− + ⇌ −+ + + KPrP Cu Cu PrP Cu ;2 2 22 2 (2)
where K1 and K2 are deﬁned as
= −
+
+K
[PrP Cu ]
[PrP][Cu ]1
2
2 (3)
= −
−
+
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[PrP Cu ][Cu ]2
2
2
2 2 (4)
Other Cu2+-binding models, such as one set of sites, two sets of
sites, or sequential binding with one site, failed to converge or
returned unrealistic values (e.g., exceedingly low N values).
Although ITC measures the total heat change associated with a
process, it should be noted that the binding-constant expressions
above (eqs 1−4) do not take into account the metal−buﬀer
interactions. Equation 5 accounts for the ACES−Cu2+ species
that are signiﬁcant at pH 7.4 and allows for the buﬀer-
independent binding constants to be obtained from the ITC
data.26,30 The concentration of ACES buﬀer used in this study
(10 mM) ensures that more than 98% of Cu2+ in solution will be
in a 1:2 Cu2+/ACES complex. It should be noted that a set of
Cu2+(ACES)2 complexes exist in solution that diﬀer in the
protonation state of ACES. These are described as MB2,
M(H−1B)B, and M(H−2B)2, where B is the deprotonated form
of ACES, H is the proton concentration, and M is the metal (eqs
6−9). At pH 7.4, the majority of Cu2+ exists as the M(H−2B)2
complex.31,32
= + +
+ +
−
− −
⎛
⎝
⎜⎜
⎞
⎠
⎟⎟
K K K K
K
K
K
K
1 [B] [B]
[B]
[H]
[B]
[H]M
M peptide ITC MB MB
2
MB
2
(H B)B
MB
2
M(H B)
2
2
2
1
2
1 2 (5)
= =K K[MB]
[M][B]
; log 4.32MB
(6)
β= =K [MB ]
[M][B]
; log 7.77MB
2
22 (7)
= =
−
−
K K
[MB ]
[H][M(H B)B]
; log 7.36M(H B)B
2
1
1 (8)
β= =
−
−
K
[MB ]
[H] [M(H B) ]
; log 15.85M(H B)
2
2
1 2
1 2 (9)
= −−K
[M peptide]
[M][peptide]M peptide (10)
The log K and log β values were obtained from ref 31 and can
also be found in NIST Database 46.31,33 Solving eq 5 yields the
buﬀer-independent binding constants shown in Table 3. A more
recent and very thorough study of Cu2+ complex formation by
ACES is available, reporting log K and log β values diﬀerent than
those used in eqs 6−9.32 Using these values to calculate the
buﬀer-independent dissociation constants (Kd) for the ﬁrst two
Cu2+-loading events to PrP(23−28, 57−98) yields the following
values: Kd1 = 2 nM, Kd2 = 210 nM. These values are 2 to 3 times
smaller than the calculated using values from ref 31. Thus, the
values in Table 3 should be considered the upper limits for the
dissociation constants.
It should be noted that there is a deviation in the ﬁt of the ITC
binding isotherm (Figure 3) at the early points in the titration
(i.e., PrP/Cu2+ stoichiometries < 1:1). This is most likely due to
the binding model used rather than the existence of ternary
complexes. Although the data is consistent with the binding of
two Cu2+ ions by the PrP(23−28, 57−98) peptide and the
process can be described as two sequential binding events, the
binding process is complex. Previous studies show that the 1:1
PrP/Cu2+ complex exists as a set of isomers involving Cu2+
coordination by multiple histidine residues.15−18 Furthermore,
His96 is involved as a dominant Cu2+-binding ligand in the 1:1
PrP/Cu2+ complex and transitions to become the sole His ligand
in the GTH−Cu2+ complex (i.e., the second Cu2+ bound).18,20
Thus, the binding constants and thermodynamic values reported
should be considered composite values for sets of related isomers
with deﬁned PrP/Cu2+ stoichiometries.
■ DISCUSSION
The use of ACES buﬀer, which chelates Cu2+, appears to have
prohibited the loading of the individual octarepeat units, a
conclusion that is based on the CD spectra and ﬁtting of the ITC
data. Because an individual octarepeat unit is reported to have a
mean Kd = 7.2 μM (log K = 5.14) for binding of Cu
2+, it is a
weaker binder to Cu2+ by orders of magnitude (cf eqs 8 and
9).24,31,32 Additionally, the buﬀer was used in a high
concentration (10 mM ACES vs 0.10 mM peptide), further
decreasing the ability of an octarepeat to bind Cu2+. It should be
noted that the isotherm in Figure 3 does not completely return to
Table 2. Best-Fit Isothermal Titration Calorimetry
Parameters and Buﬀer-Dependent Thermodynamic Values
for PrP(23−28, 57−98)a
thermodynamic parameters average values (%, n = 3)
K1
b 1.71 ± 12
K2
c 154 ± 28
ΔH1d −3.59 ± 13
ΔH2d −37.2 ± 5
TΔS1d 2.18 ± 23
TΔS2d −34.3 ± 55
aThe values shown are the average of ﬁts from three runs (Figures S2,
S3, and S4), and error is reported as ±1 standard deviation in percent.
bRepresented in (moles per liter)−1 × 104 . cRepresented in (moles per
liter)−1. dRepresented in kilocalories per mole.
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baseline (i.e., 0 kcal/mol of injectant), indicating that the system
is not fully saturated by Cu2+. This is most likely due to the
second binding site not being fully saturated at this point in the
titration. It is unlikely that the octarepeats are binding to an
appreciable extent because their characteristic CD signal is
absent when recorded under similar conditions. Hence, the
strategy of using ACES allowed for the eﬀective isolation of the
ﬁrst two binding events and simpliﬁed the ﬁtting of the ITC data.
The CD titration of PrP(23−28, 57−98) with Cu2+ in ACES is
congruous with the loading observed in other studies: a CD silent
species, attributed to coordination of Cu2+ by multiple His
residues, forms ﬁrst, followed by the binding site that is centered
on His96 and composed of the residues GTH. Figure 4 shows an
illustration of the PrP−Cu2+ species formed at diﬀerent Cu2+
loading levels; however, the last loading step was inhibited by
ACES in this study.
The use of ACES as both a buﬀer and a competitive ligand is
well suited to this particular study because it has been well
characterized; the set of complex ACES/Cu2+ stoichiometries
and binding constants are reported.31,32 However, applying
ACES to other systems and techniques must be done with care.
Besides keeping Cu2+ soluble under nonacidic conditions (pH >
5) where it would otherwise precipitate as a hydroxide complex,
ACES brings the apparent binding aﬃnity into a range accessible
by the ITC technique. For practical purposes, the upper limit of
the binding aﬃnity reliably determined by ITC is approximately
1× 107M−1 (Kd≈ 100 nM).
30 Because a large number of protein
systems have binding aﬃnities that exceed this threshold,
especially those implicated in neurodegenerative diseases,34
ACES is a practical choice as a buﬀer and a competitive ligand for
metal-binding studies of biomolecules.
The buﬀer-independent binding constants obtained from ITC
are comparable to those reported byWells et al. The dissociation
constant of the ﬁrst binding event is larger by a factor of 2 than
that reported byWells et al., and that of the second event is larger
by a factor of 4 than that reported byWells et al. (Table 3).17 It is
not surprising that some discrepancy exists among the Kd values
determined herein and those reported byWells et al. because two
diﬀerent peptide constructs were used in the study byWells et al.
(i.e., 57−91 and 91−115) to represent the diﬀerent Cu2+-
coordination sites, whereas a single peptide encompassing the
histidine-centered Cu2+-binding sites was used in this study (i.e.,
PrP(23−28, 57−98)). Furthermore, the peptide construct
consisting of residues 91−115 contains two His residues, one
at position 96 and the other at 111, and both appear to be capable
of involvement in Cu2+ binding because the Cu2+/peptide
stoichiometry depended on the solution conditions.14,35−37
Because the PrP peptide used here lacks His111, we are unable to
comment on its role in the Cu2+-binding process. The binding
constant for the octarepeat domain, represented by PrP(23−28,
57−91), has also been measured by Walter et al. using
ﬂuorescence and was found to be 0.10 nM.24 This value is over
1 order of magnitude smaller than that determined by ITC
(Table 3).
Although the thermodynamic values obtained from the ITC ﬁt
parameters show that both binding events are enthalpically
favorable (i.e., negative), the ΔH of the second binding event is
signiﬁcantly more negative. Interestingly, for the ﬁrst binding
event the entropy is favorable (i.e., positive) and compensates for
the lowerΔH associated with it, resulting in a binding constant 2
orders of magnitude stronger than that of the second binding
event. These ﬁndings may be rationalized in terms of the types of
Cu2+-coordination spheres associated with the two binding
events. The ﬁrst binding event involves the coordination of Cu2+
by three or four nitrogen atoms from the His imidazole rings,
which are all neutral and spread throughout the ﬂexible 57−98
region. The second binding event involves coordination by the
nitrogen of a single His imidazole ring plus two or three
deprotonated amide nitrogens, the latter of which are negatively
charged, and all coordinating residues are adjacent to each other.
Based on simple electrostatics, the negatively charged nitrogens
are expected to form stronger bonds with the positively charged
copper ion, resulting in a binding event with a more negative
enthalpy. In terms of entropy, the ﬁrst binding event involves
multiple isomers of the 1:1 PrP/Cu2+ complex. Regardless of the
Figure 4. Illustration of Cu2+ loading on PrP(23−28, 57−98). Note that the last step is inhibited by the individual octarepeat sites being out-competed
for Cu+ by the ACES buﬀer.
Table 3. Buﬀer-Independent Dissociation Constants (Kd) for
the First TwoCu2+-Binding Events to the PrP(23−28, 57−98)
Peptide
binding
event
this study Kd
(nM)a
reference 17 Kd
(nM)b
reference 24 Kd
(nM)c
ﬁrst 7 3 0.10
second 380 100
aEquation 5 was used for the calculation of the Kd values for this study.
bEquilibrium dialysis at pH 7.4 in 5 mM TRIS buﬀer, constructs
PrP(57−91) and PrP(91−115). cFluorescence at pH 7.4 in 25 mM
NEM buﬀer, construct PrP(23−28, 57−91).
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conformation in which apo-PrP exists before binding, it should
be readily able to coordinate a Cu2+ ion without needing
signiﬁcant energy to reorganize. The second binding event
involves the formation of a coordination sphere containing three
rings (a mix of ﬁve- and six-membered rings), which must require
more preorganization and/or must be more conformationally
restricted.
Parallels between PrP and the amyloid beta (Aβ) peptide are
worthy of comment because both contain sizable unstructured
regions and both coordinate Cu2+ with high aﬃnity.38−40 Just like
PrP, the coordination of Cu2+ by Aβ involves an equilibrium
between coordination spheres; in the case of Aβ, three diﬀerent
coordination spheres each utilize one or two His residues.18,41
Interestingly, the thermodynamic values associated with Cu2+
binding by Aβ, as represented by peptides Aβ16 or Aβ28, mirror
those of PrP: a negative ΔH and a positive TΔS.26 In fact, the
values from both studies are very close in magnitude (Aβ16 ΔH
= −2.7 kcal/mol, TΔS = +4.2 kcal/mol). As thermodynamic
values are buﬀer-dependent, it should be noted that both the PrP
study herein and the referenced Aβ study both used ACES. Thus,
a favorable entropy associated with initial metal binding may be a
general property of highly ﬂexible systems where equilibria
between coordination spheres exists and multiple histidine
residues are present.
■ CONCLUSIONS
The CD spectra and ITC data strongly suggest that PrP(23−28,
57−98) binds 2 equiv of Cu2+ when ACES is used as the buﬀer,
thus preventing the individual octarepeats from taking up Cu2+.
The use of ACES allowed for the isolation of the ﬁrst two binding
events and simpliﬁed the ﬁtting of the ITC data. The Kd values
determined by ITC, 7 and 380 nM, are well in line with those
reported by others. The ﬁrst binding event has a considerably
smaller enthalpy than the second binding event (ΔH1 =−3.59 ±
13% kcal/mol, ΔH2 = −37.2 ± 5% kcal/mol). However, the
entropy for the ﬁrst binding event is positive, whereas that of the
second is signiﬁcantly negative (TΔS1 = +2.18 ± 23% kcal/mol,
TΔS2 = −34.3 ± 55% kcal/mol), oﬀsetting the enthalpy
diﬀerence leading to a Kd for the ﬁrst binding event that is 2
orders of magnitude smaller (i.e., having a higher aﬃnity). Given
the similarity of the thermodynamic values associated with Cu2+
binding by the Aβ peptide to those reported herein for PrP, a
favorable entropy associated with initial metal binding (i.e., the
ﬁrst binding event) may be a general property of highly ﬂexible
systems containing multiple histidine residues.
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